By studying the effect of AP1M2 on the clinical prognosis and immune infiltration of tumor patients, it was found that the expression of AP1M2 in breast invasive cancer was associated with the overall survival of patients and the infiltration levels of macrophages, dendritic cells, and T cells (CD4+ and CD8+) and B cells. This evidence concerns the gene CD8A and invasive breast carcinoma.